A clinical trial evaluating secretin in ex-situ liver perfusion was listed with an updated status as of June 16, 2026. The study, titled "Secretin in Ex-situ Liver Perfusion," is registered under identifier NCT07651748. It is designated as a Phase 1/Phase 2 trial. According to the registry entry, the trial's current status is enrolling by invitation. This status indicates that participant enrollment is underway but limited to individuals specifically invited to join the study, rather than open to general recruitment. No results or outcome data are included in this update. The listing does not provide information on trial design specifics, participant numbers, or anticipated completion dates beyond what is stated here. Secretin is an approved compound, and this trial represents an investigational use in the context of ex-situ liver perfusion. Readers interested in the trial's progress can monitor the registry listing for future updates on status changes or results postings. For additional background on secretin, including its approved uses and general profile, readers can consult the compound overview.
Secretin Trial in Ex-situ Liver Perfusion Now Enrolling
See the full secretin overview
Source: https://clinicaltrials.gov/study/NCT07651748